Solutions
Company
Resources
Publications
Careers
Contact us
Skip to content
New and Noteworthy
HTA and market access
Topics
Real-world evidence
Publications
Methodology
Comparative effectiveness
Non-small cell lung cancer
Data science
Regulatory
AP - Blythe Adamson, MPH, PhD
Metastatic breast cancer
Content type
Publication summary
Video
Article
Webinar
Clear
Apply filter
Showing 9 of
0
results
Filling critical evidence generation gaps with global oncology real-world data
Real-world evidence
Video
HTA and market access
Assessing real-world data from electronic health records for health technology assessment: The SUITABILITY checklist: a good practices report of an ISPOR task force
Value in Health
Publication summary
Publications
Data science
Methodology
Regulatory
HTA and market access
AP - Blythe Adamson, MPH, PhD
Transporting comparative effectiveness evidence between countries: considerations for health technology assessment
Pharmacoeconomics
Real-world evidence
Video
Publication summary
Publications
HTA and market access
Evaluation of US oncology electronic health record real-world data to reduce uncertainty in health technology appraisals: a retrospective cohort study
BMJ Open
Real-world evidence
Publication summary
Publications
Methodology
HTA and market access
Transportability of overall survival estimates from US to UK populations receiving first-line treatment for advanced non-small-cell lung cancer
ISPOR EU
Real-world evidence
Publication summary
Publications
Methodology
HTA and market access
Data quality 2.0: The future of real-world evidence
Real-world evidence
Article
Methodology
HTA and market access
How we think about carrying evidence across country borders
Real-world evidence
Article
HTA and market access
Exploring the potential for RWD to reduce uncertainty in HTA decision-making: a case study of long-term survival outcomes
Value in Health
Real-world evidence
Publication summary
Publications
Non-small cell lung cancer
HTA and market access
Exploring the potential for EHR-derived real-world data to reduce uncertainty in HTA decision-making: a case study of long-term survival outcomes
EU ISPOR
Publications
Comparative effectiveness
Non-small cell lung cancer
HTA and market access
View more